相关实验视频

Updated: Jul 2, 2025

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption

Published on: June 20, 2017

纳米颗粒与阿尔茨海默病血管病理变化的相互作用

Ting Lei¹, Zixiao Yang¹, Hanmei Li²

¹Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, West China School of Pharmacy, Mental Health Center and National Chengdu Center for Safety Evaluation of Drugs, West China Hospital, Sichuan University, Chengdu 610041, China.

Advanced drug delivery reviews

|February 24, 2024

概括

血管功能障碍是阿尔茨海默病 (AD) 发病的核心原因,影响大脑健康和药物输送. 针对这些血管变化为AD治疗策略提供了一个有希望的新途径.

科学领域:

神经科学是一个神经科学.
血管生物学血管生物学
药理学药理学是指药理学的学科.

背景情况:

血管病理变化越来越被认为是阿尔茨海默病 (AD) 发展的关键因素.
大脑血管功能障碍,包括改变形态和减少大脑血流 (CBF),是AD的早期特征.
神经血管单元 (NVU) 的损伤,炎症和脑粉样血管病变是AD的关键血管病理.

研究的目的:

审查血管变化在阿尔茨海默氏病发病过程中的多方面的作用.
检查纳米颗粒之间的相互作用和与AD相关的大脑血管系统的病理变化.
突出针对血管的策略在阿尔茨海默病治疗中的潜力.

主要方法:

对AD血管病理学研究的综合文献综述.
对血管功能障碍导致神经退行症的机制的分析.
对纳米粒子相互作用与AD相关的血管变化的当前研究进行检查.

主要成果:

血管功能障碍促进了神经毒性物质的流入,并阻碍了来自大脑的有毒蛋白质流出 (例如,Aβ).
这些血管变化加剧神经炎症,并导致AD的神经退行过程.
血管变化显著影响大脑内药物输送和分配的有效性.

结论:

血管病理是阿尔茨海默病的关键驱动因素.
了解血管功能障碍是开发AD有效治疗策略的关键.
与病态血管系统相互作用的向输送系统可能为AD提供新的治疗突破.

关键词:

阿尔茨海默氏症的疾病是阿尔茨海默氏症.药物输送是药物输送的过程.纳米颗粒纳米颗粒血管功能障碍血管功能障碍

更多相关视频

Using Retinal Imaging to Study Dementia

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...